Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-04-2017 | Original Article

Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [⁶⁸Ga]PSMA I&T and comparison with published data of [⁶⁸Ga]PSMA HBED-CC

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 4/2017

Abstract

Purpose

To determine the detection rate of PET/CT in biochemical relapse of prostate cancer using [⁶⁸Ga]PSMA I&T and to compare it with published detection rates of [⁶⁸Ga]PSMA HBED-CC.

Methods

We performed a retrospective analysis in 83 consecutive patients with documented biochemical relapse after prostatectomy. All patients underwent whole body [⁶⁸Ga]PSMA I&T PET/CT. PET/CT images were evaluated for presence of local recurrence, lymph node metastases, and distant metastases. Proportions of positive PET/CT results were calculated for six subgroups with increasing prostate specific antigen (PSA) levels (<0.5 ng/mL, 0.5 to <1.0 ng/mL, 1.0 to <2.0 ng/mL, 2.0 to <5.0 ng/mL, 5.0 to <10.0, ≥10.0 ng/mL). Detection rates of [⁶⁸Ga]PSMA I&T were statistically compared with published detection rates of [⁶⁸Ga]PSMA HBED-CC using exact Fisher’s test.

Results

Median PSA was 0.81 (range: 0.01 – 128) ng/mL. In 58/83 patients (70 %) at least one [⁶⁸Ga]PSMA I&T positive lesion was detected. Local recurrent cancer was present in 18 patients (22 %), lymph node metastases in 29 patients (35 %), and distant metastases in 15 patients (18 %). The tumor detection rate was positively correlated with PSA levels, resulting in detection rates of 52 % (<0.5 ng/mL), 55 % (0.5 to <1.0 ng/mL), 70 % (1.0 to <2.0 ng/mL), 93 % (2.0 to <5.0 ng/mL), 100 % (5.0 to <10.0 ng/mL), and 100 % (≥10.0 ng/mL). There was no significant difference between the detection rate of [⁶⁸Ga]PSMA I&T and published detection rates of [⁶⁸Ga]PSMA HBED-CC (all p>0.05).

Conclusions

[⁶⁸Ga]PSMA I&T PET/CT has high detection rates of recurrent prostate cancer that are comparable to [⁶⁸Ga]PSMA HBED-CC.

Stewart BW, Wild CP. World cancer report 2014. International Agency for Research on Cancer: Lyon, France; 2014.

Ferlay J SI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, Accessed on 6 June 2016.

Grimm P, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J, et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int. 2012;109 Suppl 1:22–9. doi:10.1111/j.1464-410X.2011.10827.x.CrossRefPubMed

Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003;169:517–23. doi:10.1097/01.ju.0000045749.90353.c7.CrossRefPubMed

Tyson MD, Penson DF, Resnick MJ. The comparative oncologic effectiveness of available management strategies for clinically localized prostate cancer. Urol Oncol. 2016. doi:10.1016/j.urolonc.2016.03.021.

Aus G, Chapple C, Hanûs T, Irani J, Lobel B, Loch T, et al. The European Association of Urology (EAU) guidelines methodology: a critical evaluation. Eur Urol. 2009;56:859–64. doi:10.1016/j.eururo.2008.07.012.CrossRefPubMed

Ravery V. The significance of recurrent PSA after radical prostatectomy: benign versus malignant sources. Semin Urol Oncol. 1999;17:127–9.PubMed

Bott SRJ. Management of recurrent disease after radical prostatectomy. Prostate Cancer Prostatic Dis. 2004;7:211–6. doi:10.1038/sj.pcan.4500732.CrossRefPubMed

Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148–59. doi:10.1200/JCO.2007.12.4487.CrossRefPubMedPubMedCentral

10.

Davila D, Antoniou A, Chaudhry MA. Evaluation of osseous metastasis in bone scintigraphy. Semin Nucl Med. 2015;45:3–15. doi:10.1053/j.semnuclmed.2014.07.004.CrossRefPubMed

11.

Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C, et al. The detection rate of C-11 Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35:18–23. doi:10.1007/s00259-007-0581-4.CrossRefPubMed

12.

Castellucci P, Picchio M. C-11-Choline PET/CT and PSA kinetics. Eur J Nucl Med Mol Imaging. 2013;40:S36–40. doi:10.1007/s00259-013-2377-z.CrossRefPubMed

13.

Graute V, Jansen N, Ubleis C, Seitz M, Hartenbach M, Scherr MK, et al. Relationship between PSA kinetics and F-18 fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy. Eur J Nucl Med Mol Imaging. 2012;39:271–82. doi:10.1007/s00259-011-1970-2.CrossRefPubMed

14.

Castellucci P, Fuccio C, Rubello D, Schiavina R, Santi I, Nanni C, et al. Is there a role for C-11-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase < 1.5 ng/ml? Eur J Nucl Med Mol Imaging. 2011;38:55–63. doi:10.1007/s00259-010-1604-0.CrossRefPubMed

15.

Beer AJ, Eiber M, Souvatzoglou M, Schwaiger M, Krause BJ. Radionuclide and hybrid imaging of recurrent prostate cancer. Lancet Oncol. 2011;12:181–91. doi:10.1016/s1470-2045(10)70103-0.CrossRefPubMed

16.

Eder M, Schäfer M, Bauder-Wüst U, Hull W-E, Wängler C, Mier W, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23:688–97. doi:10.1021/bc200279b.CrossRefPubMed

17.

Afshar-Oromieh A, Avtzi E, Giesel F, Holland-Letz T, Linhart H, Eder M, et al. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197–209. doi:10.1007/s00259-014-2949-6.CrossRefPubMed

18.

Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668–74. doi:10.2967/jnumed.115.154153.CrossRefPubMed

19.

Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a Ga-68-labelled PSMA ligand and F-18-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:11–20. doi:10.1007/s00259-013-2525-5.CrossRefPubMed

20.

Weineisen M, Simecek J, Schottelius M, Schwaiger M, Wester HJ. Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer. EJNMMI Res. 2014;4:63. doi:10.1186/s13550-014-0063-1.CrossRefPubMedPubMedCentral

21.

Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S, et al. 68Ga- and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med. 2015;56:1169–76. doi:10.2967/jnumed.115.158550.CrossRefPubMed

22.

Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, et al. 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med. 2016;57:1006–13. doi:10.2967/jnumed.115.168443.CrossRefPubMed

23.

Martin R, Jüttler S, Müller M, Wester HJ. Cationic eluate pretreatment for automated synthesis of [⁶⁸Ga]CPCR4.2. Nucl Med Biol. 2014;41:84–9. doi:10.1016/j.nucmedbio.2013.09.002.CrossRefPubMed

24.

Rauscher I, Maurer T, Souvatzoglou M, Beer AJ, Vag T, Wirtz M, et al. Intrapatient comparison of 111In-PSMA I&T SPECT/CT and hybrid 68Ga-HBED-CC PSMA PET in patients with early recurrent prostate cancer. Clin Nucl Med. 2016. doi:10.1097/RLU.0000000000001273.PubMed

25.

Lütje S, Blex S, Gomez B, Schaarschmidt BM, Umutlu L, Forsting M, et al. Optimization of acquisition time of 68Ga-PSMA-ligand PET/MRI in patients with local and metastatic prostate cancer. PLoS One. 2016;11:e0164392. doi:10.1371/journal.pone.0164392.CrossRefPubMedPubMedCentral

26.

Sahlmann CO, Meller B, Bouter C, Ritter CO, Strobel P, Lotz J, et al. Biphasic Ga-68-PSMA-HBED-CC-PET/CT in patients with recurrent and high-risk prostate carcinoma. Eur J Nucl Med Mol Imaging. 2016;43:898–905. doi:10.1007/s00259-015-3251-y.CrossRefPubMed

27.

Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, et al. Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med. 2015;56:1185–90. doi:10.2967/jnumed.115.160382.CrossRefPubMed

28.

Husarik DB, Miralbell R, Dubs M, John H, Giger OT, Gelet A, et al. Evaluation of [F-18]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35:253–63.CrossRefPubMed

29.

Brogsitter C, Zöphel K, Kotzerke J. 18F-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients. Eur J Nucl Med Mol Imaging. 2013;40 Suppl 1:S18–27. doi:10.1007/s00259-013-2358-2.CrossRefPubMed

30.

Chen Y, Pullambhatla M, Foss CA, Byun Y, Nimmagadda S, Senthamizhchelvan S, et al. 2-(3-{1-Carboxy-5- (6- F-18 Fluoro-Pyridine-3-Carbonyl)-Amino -Pentyl}-U reido)-Pentanedioic Acid, F-18 DCFPyL, a PSMA-Based PET imaging agent for prostate cancer. Clin Cancer Res. 2011;17:7645–53. doi:10.1158/1078-0432.ccr-11-1357.CrossRefPubMedPubMedCentral

31.

Rowe SP, Macura KJ, Mena E, Blackford AL, Nadal R, Antonarakis ES, et al. PSMA-Based [F]DCFPyL PET/CT is superior to conventional imaging for lesion detection in patients with metastatic prostate cancer. Mol Imaging Biol. 2016. doi:10.1007/s11307-016-0957-6.PubMedPubMedCentral

32.

Szabo Z, Mena E, Rowe SP, Plyku D, Nidal R, Eisenberger MA, et al. Initial evaluation of [(18)F]DCFPyL for prostate-specific membrane antigen (PSMA)-Targeted PET imaging of prostate cancer. Mol Imaging Biol. 2015;17:565–74. doi:10.1007/s11307-015-0850-8.CrossRefPubMedPubMedCentral

33.

Dietlein M, Kobe C, Kuhnert G, Stockter S, Fischer T, Schomacker K, et al. Comparison of F-18 DCFPyL and Ga-68 Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biol. 2015;17:575–84. doi:10.1007/s11307-015-0866-0.CrossRefPubMedPubMedCentral

34.

Demir M, Abuqbeitah M, Uslu-Beşli L, Yıldırım Ö, Yeyin N, Çavdar İ, et al. Evaluation of radiation safety in (177)Lu-PSMA therapy and development of outpatient treatment protocol. J Radiol Prot. 2016;36:269–78. doi:10.1088/0952-4746/36/2/269.CrossRefPubMed

35.

Kratochwil C, Giesel FL, Eder M, Afshar-Oromieh A, Benesova M, Mier W, et al. Lu-177 Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:987–8. doi:10.1007/s00259-014-2978-1.CrossRefPubMed

36.

Pillai AM, Knapp FF. Lutetium-177 labeled therapeutics: ¹⁷⁷Lu-PSMA is set to redefine prostate cancer treatment. Curr Radiopharm. 2016;9:6–7.CrossRefPubMed

37.

Afshar-Oromieh A, Hetzheim H, Kübler W, Kratochwil C, Giesel FL, Hope TA, et al. Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. Eur J Nucl Med Mol Imaging. 2016;43:1611–20. doi:10.1007/s00259-016-3419-0.CrossRefPubMed

38.

Derlin T, Weiberg D, von Klot C, Wester HJ, Henkenberens C, Ross TL, et al. Ga-PSMA I&T PET/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging. Eur Radiol. 2016. doi:10.1007/s00330-016-4308-4.

39.

Kabasakal L, Demirci E, Ocak M, Akyel R, Nematyazar J, Aygun A, et al. Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. Nucl Med Commun. 2015;36:582–7. doi:10.1097/mnm.0000000000000290.CrossRefPubMed

40.

Chakraborty PS, Tripathi M, Agarwal KK, Kumar R, Vijay MK, Bal C. Metastatic Poorly Differentiated Prostatic Carcinoma With Neuroendocrine Differentiation Negative on Ga-68-PSMA PET/CT. Clin Nucl Med. 2015;40:E163–6.CrossRefPubMed

41.

Hijazi S, Meller B, Leitsmann C, Strauss A, Meller J, Ritter CO, et al. Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission tomography/computerized tomography. Prostate. 2015;75:1934–40. doi:10.1002/pros.23091.CrossRefPubMed

42.

Rauscher I, Maurer T, Fendler WP, Sommer WH, Schwaiger M, Eiber M. (68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report. Cancer Imaging. 2016;16:14. doi:10.1186/s40644-016-0072-6.CrossRefPubMedPubMedCentral

Title: Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [68Ga]PSMA I&T and comparison with published data of [68Ga]PSMA HBED-CC
Publication date: 01-04-2017
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 4/2017
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-016-3572-5

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [⁶⁸Ga]PSMA I&T and comparison with published data of [⁶⁸Ga]PSMA HBED-CC

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2017

Radionuclide therapy of malignant bone lesions

Erratum to: A rare case of rectal carcinoma and prostate carcinoma with coexistent Paget’s disease mimicking bone metastases in both 18F-FDG and 68Ga PSMA PET/CT

The reconstruction algorithm used for [68Ga]PSMA-HBED-CC PET/CT reconstruction significantly influences the number of detected lymph node metastases and coeliac ganglia

Personalized medicine: a new option for nuclear medicine and molecular imaging in the third millennium

18F-fluorodeoxyglucose positron emission tomography-computed tomography in the management of adult multisystem Langerhans cell histiocytosis

Efficacy of qualitative response assessment interpretation criteria at 18F-FDG PET-CT for predicting outcome in locally advanced cervical carcinoma treated with chemoradiotherapy